Heidelberg Pharma AG, a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announces that it will be advancing into an expanded Cohort 6 dose escalation following submission of a protocol amendment to the US Food and Drug Administration (FDA) for its Phase I/IIa study with lead ATAC candidate HDP-101 for the treatment of multiple myeloma.
– Data from HDP-101 dose escalation shows first objective responses and partial remissions in Cohort 5
– Amended protocol includes expanded Cohort 6 with dose optimization, including three parallel arms at different dosing regimens
– Revolutionizing treatment options for multiple myeloma patients with its proprietary novel payload with a unique mode of action